TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37745092
Drug: Xlimus drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xlimus drug-eluting stent
Study: 37745092
Drug: Synergy drug-eluting
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synergy drug-eluting stent
Study: 39501183
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g omega-3 fatty acids daily
Study: 37745371
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg twice daily for 12 days (50 mg twice daily on day 1 followed by 100 mg twice daily for 12 additional days)
Study: 37746735
Drug: Brensocatib 10
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib 10 mg, 25 mg, and Placebo
Study: 37746735
Drug: Brensocatib 10
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brensocatib 10 mg and 25 mg
Study: 37747168
Drug: 24-hour intravenous
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour intravenous administration of antibiotics
Study: 37747168
Drug: 24-hour oral
Normalized name: 24 Hour Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour oral administration of antibiotics
Study: 37747427
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (preoperative use)
Study: 37747970
Drug: Mental health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental health intervention including case management, psychotropic medication consultation, and psychotherapy elements.
Study: 37748109
Drug: Nine-week trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nine-week trastuzumab treatment
Study: 37748109
Drug: One-year trastuzumab
Normalized name: segesterone
DrugBank: Segesterone (DB14584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-year trastuzumab treatment
Study: 37748124
Drug: Prophylactic Radiation
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic Radiation Therapy (RT)
Study: 37748181
Drug: OD analogues
Normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: OD analogues (insulin degludec, insulin glargine U100, or insulin glargine U300)
Study: 37748693
Drug: Avelumab Q2W
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab Q2W (10 mg/kg every 2 weeks)
Study: 37748693
Drug: Avelumab QW
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab QW (10 mg/kg once weekly for 12 weeks, then Q2W)
Study: 37748849
Drug: Empiric antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric antibiotic use
Study: 37748849
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of probiotics
Study: 37749876
Drug: Acceptance-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance-based behavioral treatment for insomnia
Study: 37750183
Drug: Evogliptin 5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin 5 mg once daily
Study: 37750406
Drug: vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vonoprazan 20 mg
Study: 37750406
Drug: vonoprazan 40
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: vonoprazan 40 mg
Study: 37750660
Drug: Sequential exercise-cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential exercise-cognitive training (SEQ)
Study: 37750695
Drug: Oral tedizolid
Normalized name: Tedizolid
DrugBank: Tedizolid (DB14569)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tedizolid treatment for BJIs
Study: 37751016
Drug: Gepotidacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gepotidacin (2 × 3000 mg 10-12 h apart)
Study: 37751016
Drug: Ceftriaxone (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (500 mg, intramuscular) plus Azithromycin (1 g, oral)
Study: 37751015
Drug: AZD7442 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7442 (600 mg)
Study: 37751019
Drug: Fostemsavir +
Normalized name: fostemsavir
DrugBank: Fostemsavir (DB11796)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fostemsavir + Optimized Background Therapy (OBT)
Study: 39368039
Drug: Tucatinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucatinib (300 mg twice daily)
Study: 37751153
Drug: Intranasal glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon administration
Study: 37751153
Drug: Injectable glucagon
Normalized name: glucagon Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable glucagon administration
Study: 37751237
Drug: Just-in-time adaptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Just-in-time adaptive interventions (JITAIs) with notifications delivered up to 4 times per day and suggested daily step goals
Study: 37751286
Drug: Mindfulness Treatment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindfulness Treatment (MT)
Study: 37751301
Drug: Exendin 9-39
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exendin 9-39 (GLP-1 Receptor antagonist)
Study: 37751561
Drug: Tucatinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tucatinib (300 mg orally twice daily) and Trastuzumab (8 mg/kg intravenously followed by 6 mg/kg every 3 weeks)
Study: 37751891
Drug: Nirmatrelvir 100
Normalized name: nirmatrelvir
DrugBank: Nirmatrelvir (DB16691)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nirmatrelvir 100 mg with ritonavir 100 mg administered 12 hours before, together with, and 12 and 24 hours after nirmatrelvir
Study: 37752423
Drug: Cabozantinib 60
Normalized name: cabozantinib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 60 mg/day continuously plus lanreotide 120 mg every 28 days
Study: 37752816
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A)
Study: 37752816
Drug: TAF 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF 25 mg plus FTC 200 mg, dolutegravir 50 mg once daily (group B)
Study: 37752816
Drug: Intensified four-drug
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified four-drug regimen (TAF 10 mg plus FTC 200 mg, dolutegravir 50 mg, darunavir 800 mg, and cobicistat 150 mg once daily) (group C)
Study: 37753461
Drug: Adaptive FDG-PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive FDG-PET/CT response-guided radiotherapy (total dose 70-78 Gy)
Study: 37753808
Drug: TPMT-NUDT15 gene-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPMT-NUDT15 gene-based dosing of 6-MP (10 to 50 mg/m2)
Study: 37753808
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard dosing of 6-MP)
Study: 37754283
Drug: Tight glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight glucose control (blood-glucose level targeted at 80 to 110 mg per deciliter)
Study: 37754283
Drug: Liberal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal glucose control (insulin initiated only when blood-glucose level was >215 mg per deciliter)
Study: 37754485
Drug: Camu camu
Normalized name: CAMUSTINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camu camu (CC) added to nivolumab
Study: 37754682
Drug: Maternal antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal antibodies at birth
Study: 37755151
Drug: Neurofeedback (NF)
Normalized name: NFS-02
DrugBank: NFS-02 (DB18422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofeedback (NF) treatment, 12 sessions
Study: 37755506
Drug: Bleach baths
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleach baths (0.005% NaClO; 5-10 min duration) twice a week for 12 weeks
Study: 37756532
Drug: Ibrutinib maintenance
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib maintenance (I-M) 560 mg daily for up to 4 years
Study: 37758574
Drug: Nivolumab maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab maintenance therapy (intravenous nivolumab 8 × 240 mg every 2 weeks, followed by 480 mg every 4 weeks)
Study: 37758574
Drug: Tyrosine kinase
Normalized name: Protein-tyrosine kinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tyrosine kinase inhibitor (TKI) maintenance therapy (sunitinib 50 mg or pazopanib 800 mg once daily)
Study: 37758623
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural bupivacaine with morphine
Study: 37758649
Drug: Community-based adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based adherence support intervention for daily oral PrEP
Study: 37758676
Drug: Pain Neuroscience
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Neuroscience Education (PNE) combined with conventional treatment, 9 sessions (1 session/week for 9 weeks), each lasting 30-40 min
Study: 37758676
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (pharmacological treatment)
Study: 37758711
Drug: Pre-treatment immunogenicity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment immunogenicity analysis
Study: 37758864
Drug: Culture negative
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culture negative sepsis with 5 days of antibiotics
Study: 37759099
Drug: Biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapy achieving PASI90
Study: 37759324
Drug: Personalized multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized multimodal treatment (individualized physical exercise program combined with individualized nutritional therapy) for 12 weeks
Study: 37759489
Drug: PARPi-niraparib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARPi-niraparib therapy
Study: 37765023
Drug: High-dose Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Dexamethasone (HD-DXM)
Study: 37766218
Drug: Ultra-sensitive targeted
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-sensitive targeted PCR assay coupled with next-generation sequencing (NGS) for characterising HIV-1 DNA drug resistance mutations (DRMs).
Study: 37766505
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment (SOC)
Study: 37766731
Drug: Sustained-release β-alanine
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release β-alanine (15 g/day divided into 3 intakes for 30 days)
Study: 37766731
Drug: Sustained-release β-alanine
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release β-alanine
Study: 37767191
Drug: Anlotinib maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib maintenance treatment
Study: 37767195
Drug: Treat-to-target strategy
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treat-to-target strategy with a target LDL-C level of 50-70 mg/dL
Study: 39314261
Drug: High-intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity statin treatment
Study: 37767823
Drug: Sham bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham bright light therapy
Study: 37768018
Drug: Sex chromosome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex chromosome dosage (SCD)
Study: 37768317
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin (40 mg/kg daily, RIF40)
Study: 37768317
Drug: Standard-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose rifampicin (10 mg/kg daily, RIF10)
Study: 37768658
Drug: Tiragolumab (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiragolumab (2 mg escalating to 1200 mg) in phase 1a and combination with Atezolizumab (1200 mg every 3 weeks) in phase 1b
Study: 37768658
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tiragolumab plus Atezolizumab
Study: 37768670
Drug: CRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT plus lapatinib (1500 mg per day)
Study: 37768671
Drug: Eplontersen (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplontersen (45 mg every 4 weeks; n=144)
Study: 37769181
Drug: Irbesartan/hydrochlorothiazide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/hydrochlorothiazide combination 150/12.5 mg once daily, with up-titration to 300/12.5 mg/day and 300/25 mg/day at 4 and 8 weeks, respectively.
Study: 37769181
Drug: Irbesartan/hydrochlorothiazide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan/hydrochlorothiazide combination treatment.
Study: 37769308
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (oral 650 mg acetaminophen and 200 mg caffeine)
Study: 37769428
Drug: Inebilizumab 300
Normalized name: INEBILIZUMAB
DrugBank: Inebilizumab (DB12530)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inebilizumab 300 mg IV on Days 1 and 15
Study: 37769429
Drug: COVID-19 mRNA
Normalized name: COVID-19 mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 mRNA vaccine (2 or 3 doses after ≥1 month of subcutaneous ofatumumab 20 mg/month)
Study: 37769429
Drug: COVID-19 mRNA
Normalized name: COVID-19 mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 mRNA vaccine (3 doses)
Study: 37769429
Drug: COVID-19 mRNA
Normalized name: COVID-19 mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 mRNA vaccine (2 doses)
Study: 37769429
Drug: COVID-19 mRNA
Normalized name: COVID-19 mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 mRNA vaccine (for patients aged <40 years without previous anti-CD20 therapy)
Study: 37769610
Drug: Internal medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal medicine residents interpreting SL-ECGs
Study: 37770120
Drug: Intranasal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sufentanil
Study: 37770120
Drug: Oral/intravenous opioids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral/intravenous opioids
Study: 37770132
Drug: Noninvasive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive therapies (silver diamine fluoride, self-assembling peptide P)
Study: 37770132
Drug: Noninvasive therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive therapies (including self-assembling peptide P)
Study: 37770132
Drug: Hypothetical scenarios
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothetical scenarios with noninvasive therapies
Study: 37770278
Drug: Short screening
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short screening for CRF using five items at high frequency during therapy and lower frequency during post-treatment phase for 18 months
Study: 37770309
Drug: Delayed-release/extended-release methylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release/extended-release methylphenidate (DR/ER-MPH)
Study: 37770652
Drug: Garetosmab (activin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garetosmab (activin A-blocking antibody)
Study: 37770704
Drug: High-FN-risk chemotherapy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-FN-risk chemotherapy regimen
Study: 37770704
Drug: Low and
Normalized name: ZINC OXIDE 88 mg in 1 mL TOPICAL LOTION [Ciele Glow and Protect]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low and intermediate FN-risk chemotherapy regimens
Study: 37770881
Drug: Mind-body and
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mind-body and Art Therapies (MBATs)
Study: 37770889
Drug: Benralizumab treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab treatment
Study: 37770944
Drug: VISA-G-Norwegian questionnaire
Approvals — FDA: no, EMA: no, PMDA: no
Description: VISA-G-Norwegian questionnaire
Study: 37771545
Drug: Glecaprevir-pibrentasvir 300
Normalized name: glecaprevir / pibrentasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir-pibrentasvir 300 mg-120 mg daily for 4 weeks
Study: 37772282
Drug: Deutetrabenazine (6-48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deutetrabenazine (6-48 mg daily)
Study: 37772436
Drug: PF-06817024 (10-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06817024 (10-1000 mg single intravenous doses)
Study: 37772436
Drug: PF-06817024 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06817024 (single dose)
Study: 37772436
Drug: PF-06817024 (repeat
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06817024 (repeat doses)
Study: 37772436
Drug: PF-06817024 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06817024 (single intravenous administration)
Study: 37773184
Drug: Monovalent COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent COVID-19 vaccines
Study: 37773189
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg BID vs 10 mg BID
Study: 37773600
Drug: Treatment (rehabilitation)
Normalized name: Hongo Killer Treatment
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (rehabilitation)
Study: 37773624
Drug: Routine preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine preparations (CG)
Study: 37774185
Drug: Lidocaine 2mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2mg/kg with saline infusion (GL)
Study: 37774185
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg duloxetine (GD)
Study: 37774185
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline infusion (GC)
Study: 37774188
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine infusion (LDKI) at 0.1 mg/kg/h
Study: 37774508
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg every 4 weeks for three administrations) following long-course radiotherapy (RT) plus concomitant capecitabine (5040 cGy RT in 25-28 fractions over 5 weeks and capecitabine administered at 825 mg/m2)
Study: 37774646
Drug: Standard systolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard systolic blood pressure treatment to goal < 140 mm Hg
Study: 37774646
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (CCB) exposure
Study: 37774729
Drug: Single-dose inactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose inactivated poliovirus vaccine (IPV)
Study: 37775297
Drug: Immediate oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate oral semaglutide therapy
Study: 37775297
Drug: 2-year delay
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-year delay in oral semaglutide therapy
Study: 37775521
Drug: PHH-1V vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHH-1V vaccine formulations 10 µg
Study: 37775521
Drug: PHH-1V vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHH-1V vaccine formulations 20 µg
Study: 37775521
Drug: PHH-1V vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHH-1V vaccine formulations 40 µg
Study: 37775584
Drug: Gel containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel containing green tea extract and hyaluronic acid applied 3 times a day for 7 days
Study: 37775584
Drug: Vehicle gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle gel applied 3 times a day for 7 days
Study: 37775744
Drug: Fuzuloparib 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzuloparib 100 mg bid plus apatinib 500 mg qd
Study: 37776194
Drug: Individualized heparin-protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized heparin-protamine titration (IHPT)
Study: 37776235
Drug: Anti-TNF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF therapy (infliximab and adalimumab)
Study: 37776326
Drug: CD19/22 dual-targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19/22 dual-targeted CAR-T cell combined with tislelizumab (anti-PD-1 antibody)
Study: 37776754
Drug: Tablet-based neuroplasticity-oriented
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based neuroplasticity-oriented sensorimotor training (EG)
Study: 37776754
Drug: Tablet-based relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet-based relaxation training (CG)
Study: 37776872
Drug: Daratumumab, carfilzomib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy, administered as four 28-day cycles with daratumumab at 16 mg/kg intravenously on days 1, 8, 15, and 22, and carfilzomib at 56 mg/m2.
Study: 37776872
Drug: Daratumumab, carfilzomib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) therapy.
Study: 37776876
Drug: TV005 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV005 vaccine
Study: 37776953
Drug: YK-029A 200
Normalized name: YK-4-279
DrugBank: YK-4-279 (DB17428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YK-029A 200 mg/d (dose-expansion phase)
Study: 37776953
Drug: YK-029A (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: YK-029A (all doses during dose-escalation)